Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II concurrent chemoradiotherapy with paclitaxel + cisplatin for locally advanced esophageal squamous cell carcinoma
ChiCTR1800017039Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: 2-year local control, Median survival time and 2 more. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1800017039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017039.